Assertio Reports Fourth Quarter and Full Year 2025 Financial Results

Assertio Reports Fourth Quarter and Full Year 2025 Financial Results Assertio Reports Fourth Quarter and Full Year 2025 Financial Results Share Delivers FY2025 Net Product Sales and Adjusted EBITDA Above Guidance Expects Net Product Sales between $110M-$125M and Adjusted EBITDA between $28M-$40M in FY2026 LAKE FOREST, Ill--(BUSINESS WIRE)--Assertio Holdings, Inc. ("Assertio†or the "Company†) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated product ...